Re: RVX-297 vs RVX-208 for autoimmune indications
in response to
by
posted on
Jan 08, 2019 05:49PM
Well, if selectivity is what you are looking for then you may be interested in Abbvie's ABBV-744 with its reported 300-fold BD-2 selectivity. It's in Phase 1 for oncology.
BearDownAZ